|Awarded On||March 29, 2012|
|Title||Manufacture, Formulation, and IND-directed Toxicology of the Multifunctional Ceramide Catabolism Inhibitor D-threo-PPMP to enable Phase I Clinical Trials|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Barry J Maurer|
|Cancer Sites||Multiple Sites|
We have demonstrated that certain cellular waxes, called ‘long chain dihydroceramides’, can kill a variety of adult and pediatric cancer cells in the laboratory. We have determined that a drug, called fenretinide (4-HPR), causes cancer cells, but not normal cells, to increase their levels of certain dihydroceramide waxes up to a hundred-fold. We have determined that a second drug, called D-threo-PPMP, can maintain high levels of these dihydroceramide waxes in cancer cells by preventing the cells from changing them into other types of nontoxic waxes. We have shown that tumors growing in mice respond better to fenretinide + PPMP than they do to fenretinide-alone, and that fenretinide + PPMP is...